Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY13258 A Phase II Study of Metronomic and Targeted Anti Angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma Patients with relapsed medulloblastoma have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities. Antiangiogenetic therapy has emerged as new treatment option in solid malignancies. The frequent, metronomic schedule targets both proliferating tumor cells and endothelial cells, and minimizes toxicity. In this study the investigators will evaluate the use of biweekly intravenous bevacizumab in combination with five oral drugs (thalidomide, celecoxib, fenofibrate, and alternating cycles of daily low-dose oral etoposide and cyclophosphamide), augmented with alternating courses of intrathecal etoposide and cytarabine. The aim of the study is to extend therapy options for children with recurrent or progressive medulloblastoma, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life. The primary objective of the MEMMAT trial is to evaluate the activity of this multidrug antiangiogenic approach in these heavily pretreated children and young adults. Additionally, progression-free survival (PFS), overall survival (OS), as well as feasibility and toxicity will be examined. Study Information
STUDY13339 Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM 5.1 Primary Objectives The primary objectives of the study are: 1. To identify experimental therapies that improve OS for GBM patients in the Screening stage (Stage 1), determining if predefined patient subtypes or associated biomarkers uniquely benefit from the treatment. 2. To confirm identified efficacious experimental therapies and associated biomarker signatures in an expansion stage (Stage 2) designed to support a new drug application. 5.2 Secondary Objectives The secondary objectives of the study are: 1. To evaluate PFS by each biomarker/therapeutic combination. 2. To evaluate OS by each biomarker/therapeutic combination. 3. To determine short- and long-term safety signals and QOL measures of an experimental Arm in GBM patients versus standard of care. 5.3 Exploratory Objectives The primary objectives of the study are: 1. To generate general prognostic and predictive biomarker hypotheses. 2. To build and validate a longitudinal endpoint model of OS comprised of early assessments (performance status, disease progression, etc.) that are associated with OS. Study Information
STUDY15622 A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly Diagnosed BRAF V600 Mutant High Grade Glioma (HGG) This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib after radiation therapy may work better than treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade glioma. Study Information
STUDY17262 Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy. Study Information
STUDY17457 Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in preventing relapse in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon the 2-year progression-free survival rate (PFS) compared to relevant historical controls. Study Information